首页   按字顺浏览 期刊浏览 卷期浏览 Interferon-α2ain the Treatment of Acquired Immunodeficiency Syndrome-Related Kapo...
Interferon-α2ain the Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma

 

作者: Lydia Evans,   Loretta Itri,   Marilyn Campion,   Ruth Wyler-Plaut,   Susan Krown,   Jerome Groopman,   Howard Goldsweig,   Paul Volberding,   Susan West,   Ronald Mitsuyasu,   Zofia Dziewanowska,  

 

期刊: Journal of Immunotherapy  (OVID Available online 1991)
卷期: Volume 10, issue 1  

页码: 39-50

 

ISSN:1524-9557

 

年代: 1991

 

出版商: OVID

 

关键词: AIDS-related KS;Interferon-a2a;CD4 lymphocyte count;Response rate;Survival

 

数据来源: OVID

 

摘要:

SummaryIn a series of studies, recombinant interferon-α2a(rIFNα2a, Roferon- A) was administered alone (273 men) or combined with vinblastine (91 men) to patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma (KS). Patients were treated with daily doses of rIFNα2aranging from 3 to 54 million international units (I.U.) administered intramuscularly. A dose of 36 million I.U. daily for approximately 10 weeks followed by a three times weekly maintenance schedule with the same dose resulted in the best overall therapeutic benefit. An escalating-dose regimen of 3, 9, and 18 million I.U. daily, each for 3 days, followed by 36 million I.U. daily, produced equivalent therapeutic benefit with amelioration of acute toxicity in some patients. Response was more likely in patients without a history of opportunistic infection or B symptoms (fever, night sweats, or weight loss). Response rate increased with increasing baseline CD4 lymphocyte count and was 45.5% in patients with a CD4 count of greater than 400/mm3. Responding patients with a CD4 count of greater than 200/mm3had a distinct survival advantage over patients who had similar CD4 counts but whose tumors did not regress with therapy. The addition of vinblastine increased toxicity and did not improve the response rate or prolong survival. Side effects included fatigue, fever, chills, myalgias, headaches, anorexia, nausea, diarrhea, and dizziness. Mild abnormalities in hematologic and liver function tests occurred in some patients. Most adverse effects diminished or resolved with continued therapy. We conclude that rIFNα2aoffers important therapeutic benefit in a select group of patients with AIDS-related KS.

 

点击下载:  PDF (950KB)



返 回